Literature DB >> 21150327

Role of Cdk4 in lymphocyte function and allergen response.

Yu-Hua Chow1, Xiao Dong Zhu, Li Liu, Barbara R Schwartz, Xiao Zhu Huang, John M Harlan, Lynn M Schnapp.   

Abstract

We recently described a new adhesion pathway in lymphocytes that is dependent on Cyclin-dependent kinase (Cdk) 4 activity and mediates lymphocyte interactions with endothelial matrix. We showed that Cdk4(-/-) mice had impaired recruitment of lymphocytes following bleomycin model of acute lung injury. In this study, we characterized the development and function of hematopoietic cells in Cdk4(-/-) mice and assessed the response of Cdk4(-/-) mice to allergen challenge. Cdk4(-/-) mice had hypoplastic thymuses with decreased total thymocyte cell numbers and increased CD4/CD8 double negative cells. Cdk4(-/-) bone marrow (BM) chimeric mice showed similar findings. Thymocytes from either Cdk4(-/-) or Cdk4(-/-) BM chimeric mice proliferated equally well as wild type controls in response to IL-2 activation. However Cdk4(-/-) thymocytes had decreased adhesion to both endothelial cell matrix and fibronectin compared to wildtype (WT) controls, whereas Cdk4(-/-) and WT splenocytes had similar adhesion. When Cdk4(-/-) BM chimeric mice and wild type BM chimeric mice were sensitized and challenged by intranasal administration of ovalbumin, we found no differences in allergic responses in the lung and airways between the two groups, as measured by inflammatory cell infiltrate, airway hyperreactivity, IgE levels and cytokine levels. In summary, we show that Cdk4 plays a previously unrecognized role in thymocyte maturation and adhesion, but is not required for thymocyte proliferation. In addition, Cdk4 is not required for lymphocyte trafficking to the lung following allergen sensitization and challenge.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21150327      PMCID: PMC3047815          DOI: 10.4161/cc.9.24.14209

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  15 in total

1.  Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6.

Authors:  Marcos Malumbres; Rocío Sotillo; David Santamaría; Javier Galán; Ana Cerezo; Sagrario Ortega; Pierre Dubus; Mariano Barbacid
Journal:  Cell       Date:  2004-08-20       Impact factor: 41.582

Review 2.  Living with or without cyclins and cyclin-dependent kinases.

Authors:  Charles J Sherr; James M Roberts
Journal:  Genes Dev       Date:  2004-11-15       Impact factor: 11.361

3.  Constitutive activation of integrin alpha 4 beta 1 defines a unique stage of human thymocyte development.

Authors:  D R Salomon; C F Mojcik; A C Chang; S Wadsworth; D H Adams; J E Coligan; E M Shevach
Journal:  J Exp Med       Date:  1994-05-01       Impact factor: 14.307

4.  Targeted disruption of CDK4 delays cell cycle entry with enhanced p27(Kip1) activity.

Authors:  T Tsutsui; B Hesabi; D S Moons; P P Pandolfi; K S Hansel; A Koff; H Kiyokawa
Journal:  Mol Cell Biol       Date:  1999-10       Impact factor: 4.272

5.  Selective usage of D-type cyclins in lymphoid malignancies.

Authors:  R Suzuki; H Kuroda; H Komatsu; Y Hosokawa; Y Kagami; M Ogura; S Nakamura; Y Kodera; Y Morishima; R Ueda; M Seto
Journal:  Leukemia       Date:  1999-09       Impact factor: 11.528

6.  Cell adhesion and migration are regulated at distinct stages of thymic T cell development: the roles of fibronectin, VLA4, and VLA5.

Authors:  L Crisa; V Cirulli; M H Ellisman; J K Ishii; M J Elices; D R Salomon
Journal:  J Exp Med       Date:  1996-07-01       Impact factor: 14.307

Review 7.  Regulation of the cytoskeleton: an oncogenic function for CDK inhibitors?

Authors:  Arnaud Besson; Richard K Assoian; James M Roberts
Journal:  Nat Rev Cancer       Date:  2004-12       Impact factor: 60.716

8.  Loss of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in beta-islet cell hyperplasia.

Authors:  S G Rane; P Dubus; R V Mettus; E J Galbreath; G Boden; E P Reddy; M Barbacid
Journal:  Nat Genet       Date:  1999-05       Impact factor: 38.330

9.  Requirement for cyclin D3 in lymphocyte development and T cell leukemias.

Authors:  Ewa Sicinska; Iannis Aifantis; Laurent Le Cam; Wojciech Swat; Christine Borowski; Qunyan Yu; Adolfo A Ferrando; Steven D Levin; Yan Geng; Harald von Boehmer; Piotr Sicinski
Journal:  Cancer Cell       Date:  2003-12       Impact factor: 31.743

10.  Differential T cell function and fate in lymph node and nonlymphoid tissues.

Authors:  Nicola L Harris; Victoria Watt; Franca Ronchese; Graham Le Gros
Journal:  J Exp Med       Date:  2002-02-04       Impact factor: 14.307

View more
  8 in total

Review 1.  CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought.

Authors:  Mary E Klein; Marta Kovatcheva; Lara E Davis; William D Tap; Andrew Koff
Journal:  Cancer Cell       Date:  2018-05-03       Impact factor: 31.743

Review 2.  Cyclin D as a therapeutic target in cancer.

Authors:  Elizabeth A Musgrove; C Elizabeth Caldon; Jane Barraclough; Andrew Stone; Robert L Sutherland
Journal:  Nat Rev Cancer       Date:  2011-07-07       Impact factor: 60.716

3.  Proliferation of hippocampal progenitors relies on p27-dependent regulation of Cdk6 kinase activity.

Authors:  Nicolas Caron; Emmanuelle C Genin; Quentin Marlier; Sébastien Verteneuil; Pierre Beukelaers; Laurence Morel; Miaofen G Hu; Philip W Hinds; Laurent Nguyen; Renaud Vandenbosch; Brigitte Malgrange
Journal:  Cell Mol Life Sci       Date:  2018-05-04       Impact factor: 9.261

4.  Short communication: adhesion pathways utilized by HIV-infected lymphocytes.

Authors:  Yu-hua Chow; Li Liu; Barbara Schwartz; John M Harlan; Lynn M Schnapp
Journal:  AIDS Res Hum Retroviruses       Date:  2012-04-13       Impact factor: 2.205

5.  CDK4: A Key Player in the Cell Cycle, Development, and Cancer.

Authors:  Stacey J Baker; E Premkumar Reddy
Journal:  Genes Cancer       Date:  2012-11

6.  Decitabine inhibits T cell proliferation via a novel TET2-dependent mechanism and exerts potent protective effect in mouse auto- and allo-immunity models.

Authors:  Xue Wang; Jun Wang; Yong Yu; Tonghui Ma; Ping Chen; Bing Zhou; Ran Tao
Journal:  Oncotarget       Date:  2017-05-22

Review 7.  CDK4: a master regulator of the cell cycle and its role in cancer.

Authors:  Stacey J Baker; Poulikos I Poulikakos; Hanna Y Irie; Samir Parekh; E Premkumar Reddy
Journal:  Genes Cancer       Date:  2022-08-25

8.  Targeting CDK4 overcomes EMT-mediated tumor heterogeneity and therapeutic resistance in KRAS-mutant lung cancer.

Authors:  Aparna Padhye; Jessica M Konen; B Leticia Rodriguez; Jared J Fradette; Joshua K Ochieng; Lixia Diao; Jing Wang; Wei Lu; Luisa S Solis; Harsh Batra; Maria G Raso; Michael D Peoples; Rosalba Minelli; Alessandro Carugo; Christopher A Bristow; Don L Gibbons
Journal:  JCI Insight       Date:  2021-09-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.